ACHV Valuation

Achieve Life Sciences Inc

Add to Watchlist

Advanced Chart

4.590

-0.15(-3.165%)1D

ACHV Relative Valuation

ACHV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ACHV is overvalued; if below, it's undervalued.

Historical Valuation

Achieve Life Sciences Inc (ACHV) is now in the Fair zone, suggesting that its current forward PS ratio of 4.74 is considered Fairly compared with the five-year average of -2.79. The fair price of Achieve Life Sciences Inc (ACHV) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：4.59

Fair

-4.16

Trailing

Forward

0.00

EV/EBITDA

Achieve Life Sciences Inc. (ACHV) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.28. The thresholds are as follows: Strongly Undervalued below -1.44, Undervalued between -1.44 and -0.86, Fairly Valued between 0.29 and -0.86, Overvalued between 0.29 and 0.87, and Strongly Overvalued above 0.87. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-4.11

EV/EBIT

Achieve Life Sciences Inc. (ACHV) has a current EV/EBIT of -4.11. The 5-year average EV/EBIT is -1.92. The thresholds are as follows: Strongly Undervalued below -4.08, Undervalued between -4.08 and -3.00, Fairly Valued between -0.84 and -3.00, Overvalued between -0.84 and 0.24, and Strongly Overvalued above 0.24. The current Forward EV/EBIT of -4.11 falls within the Strongly Undervalued range.

4.59

Achieve Life Sciences Inc. (ACHV) has a current PS of 4.59. The 5-year average PS is 192.38. The thresholds are as follows: Strongly Undervalued below -950.33, Undervalued between -950.33 and -378.97, Fairly Valued between 763.74 and -378.97, Overvalued between 763.74 and 1335.09, and Strongly Overvalued above 1335.09. The current Forward PS of 4.59 falls within the Historic Trend Line -Fairly Valued range.

-5.62

P/OCF

Achieve Life Sciences Inc. (ACHV) has a current P/OCF of -5.62. The 5-year average P/OCF is -1.84. The thresholds are as follows: Strongly Undervalued below -5.05, Undervalued between -5.05 and -3.44, Fairly Valued between -0.24 and -3.44, Overvalued between -0.24 and 1.36, and Strongly Overvalued above 1.36. The current Forward P/OCF of -5.62 falls within the Strongly Undervalued range.

-5.97

P/FCF

Achieve Life Sciences Inc. (ACHV) has a current P/FCF of -5.97. The 5-year average P/FCF is -2.14. The thresholds are as follows: Strongly Undervalued below -5.62, Undervalued between -5.62 and -3.88, Fairly Valued between -0.40 and -3.88, Overvalued between -0.40 and 1.34, and Strongly Overvalued above 1.34. The current Forward P/FCF of -5.97 falls within the Strongly Undervalued range.

Achieve Life Sciences Inc (ACHV) has a current Price-to-Book (P/B) ratio of 5.65. Compared to its 3-year average P/B ratio of 25.69 , the current P/B ratio is approximately -78.00% higher. Relative to its 5-year average P/B ratio of 16.77, the current P/B ratio is about -66.30% higher. Achieve Life Sciences Inc (ACHV) has a Forward Free Cash Flow (FCF) yield of approximately -0.16%. Compared to its 3-year average FCF yield of -32.01%, the current FCF yield is approximately -99.50% lower. Relative to its 5-year average FCF yield of -36.07% , the current FCF yield is about -99.55% lower.

5.47

P/B

Median3y

25.69

Median5y

16.77

-0.17

FCF Yield

Median3y

-32.01

Median5y

-36.07

Competitors Valuation Multiple

The average P/S ratio for ACHV's competitors is 4.49, providing a benchmark for relative valuation. Achieve Life Sciences Inc Corp (ACHV) exhibits a P/S ratio of 4.59, which is 2.19% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ACHV.O

Achieve Life Sciences Inc

Sagimet Biosciences Inc

7.69

312.42M

ELDN.O

Eledon Pharmaceuticals Inc

2.06

123.36M

AVIR.O

Atea Pharmaceuticals Inc

3.27

259.50M

VNDA.O

Vanda Pharmaceuticals Inc

Puma Biotechnology Inc

4.90

-32.36%

301.84M

Performance Decomposition

Market capitalization of ACHV increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ACHV in the past 1 year is driven by Unknown.